The decision by Pfizer Inc. and partner BioNTech SE to boost the enrollment of their Phase III coronavirus vaccine study comes as the trial encounters a growing challenge in achieving diverse enrollment.
Pfizer has seen the proportion of minority subjects in the trial of its mRNA vaccine candidate decrease as the overall...







